Table 3.
Associations of urinary NGAL and KIM-1 with 2-year and 10-year progression to ESRD
| ESRD events |
Model 1a HR (95% CI) |
Model 2b HR (95% CI) |
Model 3c HR (95% CI) |
|
|---|---|---|---|---|
| NGAL | ||||
| ESRD at 2-year follow-up | ||||
| NGAL T1 (reference) | 5/483 (1%) | |||
| NGAL T2 versus T1 | 14/484 (3%) | 3.25 (1.16–9.13) | 2.04 (0.73–5.71) | 1.19 (0.47–3.02) |
| NGAL T3 versus T1 | 37/484 (8%) | 10.66 (3.81–29.82) | 4.79 (1.65–13.88) | 1.84 (0.66–5.15) |
| NGAL (per doubling) | 56/1451 (4%) | 1.62 (1.43–1.83) | 1.45 (1.24–1.71) | 1.19 (0.99–1.42) |
| ESRD entire follow-up period | ||||
| NGAL T1 (reference) | 54/483 (11%) | |||
| NGAL T2 versus T1 | 95/484 (20%) | 2.36 (1.67–3.33) | 1.86 (1.29–2.68) | 1.41 (0.99–2.01) |
| NGAL T3 versus T1 | 108/484 (22%) | 2.91 (2.02–4.20) | 2.08 (1.43–3.02) | 1.30 (0.89–1.90) |
| NGAL (per doubling) | 257/1451 (18%) | 1.25 (1.17–1.34) | 1.18 (1.10–1.28) | 1.06 (0.98–1.14) |
| KIM-1 | ||||
|---|---|---|---|---|
| ESRD at 2-year follow-up | ||||
| KIM T1 (reference) | 13/483 (3%) | |||
| KIM1 T2 versus T1 | 24/484 (5%) | 3.68 (1.80–7.53) | 1.99 (0.98–4.05) | 1.50 (0.69–3.24) |
| KIM1 T3 versus T1 | 19/483 (4%) | 4.78 (2.18–10.48) | 1.41 (0.53–3.72) | 1.09 (0.38–3.15) |
| KIM-1 (per doubling) | 56/1450 (4%) | 1.93 (1.51–2.46) | 1.24 (0.86–1.79) | 1.21 (0.82–1.77) |
| ESRD entire follow-up period | ||||
| KIM T1 (reference) | 78/483 (16%) | |||
| KIM1 T2 versus T1 | 91/484 (19%) | 1.83 (1.33–2.51) | 1.33 (0.95–1.86) | 1.23 (0.88–1.72) |
| KIM1 T3 versus T1 | 88/483 (18%) | 2.54 (1.78–3.64) | 1.23 (0.83–1.84) | 1.29 (0.85–1.96) |
| KIM-1 (per doubling) | 257/1450 (18%) | 1.48 (1.33–1.66) | 1.13 (0.99–1.29) | 1.24 (1.08–1.42) |
CI, confidence interval; eGFRcr-cys, estimated glomerular filtration rate creatinine-cystatin; ESRD, end-stage renal disease; HR, hazard ratio; KIM-1, kidney injury molecule−1; NGAL, neutrophil gelatinase−associated lipocalin, T1, tertile 1; T2, tertile 2; T3, tertile 3.
a
Model 1: Age, sex, race, socioeconomic status, urine creatinine.
b
Model 2: 1+ diabetes, systolic blood pressure, diastolic blood pressure, hypertension, smoking, body mass index, alcohol use, albumin-to-creatinine ratio, C-reactive protein.
c
Model 3: 2+ eGFRcr-cys.